Cell Therapy for Nonischemic Cardiomyopathy
نویسنده
چکیده
Currently, nonischemic dilated cardiomyopathy (NICM) represents the leading cause of advanced heart failure, accounting for >50% of all heart transplantation procedures. We propose that when compared with patients with ischemic heart failure (IHF), patients with NICM demonstrate a more favorable clinical response to cell therapy, which offers a potential novel promising treatment approach for this patient population.
منابع مشابه
CD34+ stem cell therapy in nonischemic dilated cardiomyopathy patients.
Recent trends indicate that patients with nonischemic dilated cardiomyopathy represent the largest subpopulation of heart failure patients with a significant need for alternative treatment modalities. Similar to patients with ischemic cardiomyopathy, patients with nonischemic dilated cardiomyopathy have been found to have myocardial regions with flow abnormalities, which may represent targets f...
متن کاملPerivalvular fibrosis and monomorphic ventricular tachycardia: toward a unifying hypothesis in nonischemic cardiomyopathy.
The basis for arrhythmogenesis in patients with nonischemic cardiomyopathy and ventricular tachycardia (VT) needs further elucidation. Cardiac arrest and/or nonsustained VT are common arrhythmia presentations in the setting of nonischemic cardiomyopathy, with sustained monomorphic VT being relatively uncommon.1,2 Importantly, bundlebranch reentrant VT is identified as the VT mechanism in a sign...
متن کاملAre familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF.
control (10%) arms. In the control group, 2 patients died. There was no significant change in functional class or left ventricular function in this group. In summary, 24 patients underwent intracoronary stem cell injection with coronary sinus blockage. Four patients died during the 6-month follow-up. Overall EF showed a small but significant improvement of 5.4%. There was a decrease in end-syst...
متن کاملIntravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
RATIONALE Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. OBJECTIVE To assess the safe...
متن کاملIncidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up
INTRODUCTION The aim of the study was to investigate at long-term follow-up the incidence of appropriate implantable cardioverter-defibrillator (ICD) shocks and of all-cause mortality in patients with ICDs with ischemic cardiomyopathy versus nonischemic cardiomyopathy. MATERIAL AND METHODS ICDs were implanted in 485 patients with ischemic cardiomyopathy and in 299 patients with nonischemic ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017